



INFORMED CONSENT

CHRISTINE GRADY
DEPARTMENT OF BIOETHICS
NIH CLINICAL CENTER

Disclaimer



- ▶ The views expressed are mine and do not necessarily represent the policies of the Department of Bioethics, National Institutes of Health, or the Department of Health and Human Services.
- ▶ I have no conflicts of interest to disclose

Informed consent



- ▶ The BASICS
- ▶ CHANGES
- ▶ ENDURING AND EMERGING CHALLENGES

Consent

- ▶ A moral and legal protection from unauthorized invasions of one's body and property
- ▶ A facilitative moral power- making certain interpersonal conduct permissible that otherwise would be prohibited as wrong
- ▶ Well entrenched in societal values, jurisprudence, and health care



Informed consent



- ▶ Authorization of an activity based on understanding what the activity entails.
- ▶ A legal, regulatory, and ethical requirement in most health care and most research with human subjects
- ▶ A process of reasoned decision making (not a form or an episode)
- ▶ Autonomous authorization (Faden and Beauchamp 1986)

Ethical requirement



- ▶ Respect for autonomy - an individual's capacity and right to define his/her own goals and make choices consistent with those goals.
- ▶ Respect for persons requires that subjects, to the degree that they are capable, be given the opportunity to choose what shall or shall not happen to them. This opportunity is provided...[when] informed consent are satisfied. *Belmont Report*

Informed consent in clinical research

- ▶ The goal of research is to produce knowledge, not always benefit to the participant.
- ▶ Special importance to the ethical injunction against using people for the benefit of others without their valid consent.
- ▶ One aspect of conducting ethical clinical research



Informed consent in clinical research



- ▶ Required by virtually all codes of research ethics, regulations, and laws (limited exceptions):
 - ▶ US Federal Regulations (Common Rule (45CFR46) and FDA (21CFR50))
 - ▶ ICH-GCP
 - ▶ Declaration of Helsinki, CIOMS
 - ▶ National, state, institutional requirements

Research Informed consent: Regulatory requirements

- ▶ ...no investigator may involve a human being as a subject in research ..unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative... (45CFR.46.116, 21CFR.50.20) (limited exceptions)
- ▶ Informed consent must be sought prospectively, and documented to the extent required under 45 CFR 46.117 and 21CFR50.27.

Informed consent


- ▶ “Informed consent involves providing a potential subject with adequate information to allow for an informed decision about participation in the clinical investigation, facilitating the potential subject’s comprehension of the information, providing adequate opportunity for the potential subject to ask questions and to consider whether to participate, obtaining the potential subject’s voluntary agreement to participate, and continuing to provide information as the clinical investigation progresses or as the subject or situation requires.”
- ▶ US FDA Informed Consent Guidance Sheet, July 2014

Elements of informed consent

- ▶ (Capacity to consent)
- ▶ Disclosure of information
- ▶ Understanding
- ▶ Voluntariness
- ▶ (Consent authorization)

Decisions about Disclosure of information

- ▶ What information should be disclosed?
- ▶ How should the information be presented?
- ▶ Circumstances and setting?




Disclosure of information



- ▶ Written consent form
 - ▶ Study summary—explanation of what the study is about, the procedures, related risks and possible benefits, alternatives, rights;
 - ▶ Elements required by regulations
- ▶ Advertisements, fliers, brochures
- ▶ (Reviewed and approved by IRB)

Consent forms

- ▶ Writing readable, understandable consent forms that explain the study
- ▶ Consider length, format, reading level, complexity
- ▶ Using consent forms in discussion



Easy-to-read informed consent documents

- ▶ Familiar, consistent words, Active voice and personal pronouns
- ▶ Short, simple, direct sentences with limited line length
- ▶ Short paragraphs, one idea per paragraph.
- ▶ Clear, logically sequenced ideas
- ▶ Highlight Important points
- ▶ Avoid acronyms and abbreviations
- ▶ Format (headers, white space, graphics, font, bold)
- ▶ **From NCI Simplification of Informed Consent Documents, Appendix 3.**
<<http://www.cancer.gov/clinicaltrials/understanding/simplification-of-informed-consent-docs/page1>

Health literacy



- ▶ “In ensuring that information is understandable, it should be noted that
 - ▶ more than one-third of U.S. adults, 77 million people, have basic or below basic health literacy,
 - ▶ Limited health literacy affects adults in all racial and ethnic groups,
 - ▶ More than one-half of U.S. adults have basic or below basic quantitative literacy and are challenged by numerical presentations of health, risk, and benefit data.

FDA Informed Consent Guidance Sheet, July 2014

Length and readability

▶ Reading level is high

- ▶ Consent forms and templates usually written at or above the 11th grade level LoVerde et al, 1989; Grossman et al 1994; Paasche-Orlow et al., 2003; Sharp 2004

▶ Consent forms are long

- ▶ Consent documents have increased in length over time Baker and Taub, 1983; LoVerde et al 1989; Tarnowski et al 1990; Beardsley et al 2007, Albala et al. 2010

▶ Missing required or relevant elements

- ▶ Silverman et al. *Critical Care Medicine* 2001; Horng et al, *NEJM* 2002; Beardsley et al. *JCO* 2007; Abeyseena C et al *Ind J Med Ethics* 2012



Informed consent (revised

Common Rule)

- ▶ §___.116 (a)(5)(i) Informed consent *must begin with a concise and focused presentation of the key information* that is most likely to assist a prospective subject or LAR in understanding the reasons why one might or might not want to participate
- ▶ ...organized in a way that facilitates comprehension.

Challenges



- ▶ It is difficult to write concise and clear consent forms
“Easy reading is damn hard writing.”
Nathaniel Hawthorne ~1840, Maya Angelou ~2000
- ▶ Written informed consent protects the institution, sponsor, investigator
- ▶ IRBs often make consent forms longer and more complex

Prototypical research informed consent

- ▶ Discussion of study information
- ▶ Written consent form
- ▶ Signatures



MEDICAL RECORD	CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY
• Adult Patient or • Parent, for Minor Patient	
INSTITUTE:	
STUDY NUMBER:	PRINCIPAL INVESTIGATOR:
STUDY TITLE:	
Initial Review Approved by the IRB on Standard	Date Posted to Web:
INTRODUCTION	
We invite you to take part in a research study at the National Institutes of Health (NIH).	
First, we want you to know that:	
Taking part in NIH research is entirely voluntary.	
You may choose not to take part, or you may withdraw from the study at any time. In either case, you will not lose any benefits to which you are otherwise entitled. However, to receive care at the NIH, you must be taking part in a study or be under evaluation for study participation.	

Presentation



Setting



Elements of informed consent

- ▶ Disclosure of information
- ▶ *Understanding*
- ▶ Voluntariness
- ▶ Consent authorization




Participant Understanding



- ▶ Studies continue to show that research participants have variable understanding e.g. *Mandava A et al J Med Ethics 2012*
- ▶ Range of understanding about research purpose and nature (27% -100%) *Krosin et al 2006; Joffe et al 2001; Pace et al. 2005; Criscione et al. 2003*
- ▶ Range of understanding about research risks (28%-100%) *Bergler 1980; Joffe et al. 2001; Leach et al, 1999; Dougherty et al 2000*
- ▶ Range of understanding about randomization (21%-42%) *Harrison et al 1995; Hietanen 2000; Pace et al. 2005; Howard 1981*

Fig. 2. Participants' understanding of components of informed consent in clinical trials, by meta-analysis^a



^a The number of studies included in the evaluation of each component is given.

Understanding: issues and challenges

- ▶ What affects understanding? age, education, expectations, disclosure
- ▶ How is/should understanding be assessed?
- ▶ How much should participants understand?
- ▶ What happens (or should happen) when participants don't understand?



Table. Steps for Validating Potential Research Participants' Consent to Research


	Risk/Benefit Profile for Participants ^a		
	Low Risk	Moderate Risk and High Risk/ Potential Benefit	High Risk/ Little or No Potential Benefit
Example	Buccal sampling; few blood draws; standardized surveys	Phase 2 study; research biopsy	Treatment withdrawal for serious condition; challenge studies with high risk
Domains of valid consent			
Competence	Assume ^b	Assume ^b	Consider formal assessment
Understanding	Assume (following explanation of study) ^b	Informal or brief formal assessment	Formal assessment by team or independent party
Voluntariness	Assume ^b	Informal assessment	Formal assessment by team or independent party

^aAs determined by the institutional review board.
^bUnless there is reason for concern.

Wendler D How to enroll participants in research ethically. *JAMA* 2011

Understanding

- ▶ Knowledge of relevant information
- ▶ Appreciation of how it applies
- ▶ Therapeutic misconception



Therapeutic Misconception

- ▶ When a research participant fails to recognize how individualized medical care (i.e. physician obligation to make medical decisions in the patient's best medical interests) may be compromised by research procedures [Appelbaum et al. IRB 2004](#)
- ▶ Failure to recognize the differences between research and ordinary care negates the ability to provide meaningful informed consent. [Appelbaum et al. KIE 2006](#)



Research on improving understanding

- ▶ Multimedia (e.g. audiotapes, videotapes, interactive computers)
- ▶ Enhanced consent form (e.g. modified style, format or length)
- ▶ Extended discussion (with team member or neutral educator)
- ▶ Test/feedback (e.g. quizzes and review)
- ▶ Mixed and miscellaneous (e.g. online presentations, supplementary vignettes, etc)

Strategies to improve understanding

- ▶ Does a simpler, more concise consent form affect study understanding or satisfaction with consent?
- ▶ RCT
- ▶ Healthy volunteers: Flu vaccine studies, Phase 1 drug development. *Stunkel et al IRB 2010; Enama et al Cont Clin Trial 2012*
- ▶ Patient volunteers: Multinational HIV study. *Grady et al PloS One 2017*

IRB ETHICS & HUMAN RESEARCH

Just-August 2010 • Volume 32, Number 4

Comprehension and Informed Consent: Assessing the Effect of a Short Consent Form

BY LEANNE STUNKEL, MEREDITH BENSON, LOUISE McLELLAN, NINET SINAI, GABRIELLA BEDARIDA, EZEKIEL EMANUEL, AND CHRISTINE GRADY

Although informed consent is a fundamental ethical requirement for research with humans, many studies indicate that research volunteers often do not understand critical aspects of the research in which they are participating, suggesting that the "informed" part of consent to participate is imperfectly realized.

ing, satisfaction with the informed consent process, or both.⁵ However, not all studies found improvement.⁶ Moreover, these studies have important limitations. Many used consent documents in hypothetical situations rather than in actual research studies.⁷ Also, most of the consent studies involved participants who were

Comprehension and Informed Consent: Assessing the Effect of a Short Consent Form

Learnie Stunkel, Meredith Benson, Louise Mclellan, Ninet Sinai, Gabriella Bedarida, Ezekiel Emanuel, and Christine Grady

Assessing the Readability of Non-English-Language Consent Forms: The Case of Kiswahili for Research Conducted in Kenya

Caroline Kibingi and Nancy E. Kass

Contents lists available at ScienceDirect

Contemporary Clinical Trials

journal homepage: www.elsevier.com/locate/conclitrial

Randomization to standard and concise informed consent forms: Development of evidence-based consent practices^{1,2}

Mary E. Enama^{3,4}, Zonghui Hu⁵, Ingelise Gordon⁶, Pamela Costner⁷, Julie E. Ledgerwood⁸, Christine Grady⁹ and the VRC 306 and 307 Consent Study Teams

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20895-3017, United States

² Paediatric Research Branch, Division of Clinical Research, NIHR, NRI, Bethesda, MD 20892, United States

³ Department of Biostatistics, NIH Clinical Center, Bethesda, MD 20892, United States

ARTICLE INFO

ABSTRACT

Background: Consent to participate in research is an important component of the conduct of ethical clinical trials. Current consent practices are largely policy-driven. This study was conducted to assess comprehension of study information and satisfaction with the consent form between subjects randomized to concise or to standard informed consent forms as one approach to developing evidence-based consent practices.

Methods: Participants (N=111) who enrolled into two Phase I investigational influenza vaccine protocols (VRC 306 and VRC 307) at the NIH Clinical Center were randomized to one of two IRB-approved consents; either a standard or concise form. Concise consents had an average of 63% fewer words. All other aspects of the consent process were the same. Questionnaires about the study and the consent process were completed at enrollment and at the last visit in both studies.

Results: Subjects using concise consent forms scored as well as those using standard length consents on measures of comprehension (7 versus 7, p=0.79) and 20 versus 21, p=0.13), however this trend was for the concise consent arm in vaccine findings further informed. Both

PLOS ONE

RESEARCH ARTICLE

A randomized trial comparing concise and standard consent forms in the START trial

Christine Grady¹, Giota Touloumi², A. Sarah Walker³, Mary Smolaks⁴, Shweta Sharma⁵, Abdel G. Habiber⁶, Nicos Pantazis⁷, Jorge Tavel⁸, Eric Florenco⁹, Adriana Sanchez⁴, Fleur Hudson¹⁰, Antonios Papadopoulos¹¹, Ezekiel Emanuel¹², Megan Clewett¹³, David Munroe¹⁴, Eileen Denning¹⁵, the INSIGHT START Informed Consent Substudy Group¹⁶

OPEN ACCESS

Citation: Grady C, Touloumi G, Walker AS, Smolaks M, Sharma S, Babiker AG, et al. (2017) A randomized trial comparing concise and standard consent forms in the START trial. PLoS ONE 12(4): e0172607. <https://doi.org/10.1371/journal.pone.0172607>

Editor: Kerry Woolf, University of Liverpool, UNITED KINGDOM

Received: July 7, 2016

Accepted: January 24, 2017

Published: April 26, 2017

Copyright: This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Participant level data are not provided to open access due to ethical and legal obligations to the participants in the clinical trial. Aggregate data will be available to all registered investigators at the principal investigator's site. The option to remove consent forms from the public domain is available.

Background

Improving the effectiveness and efficiency of research informed consent is a high priority. Some express concern about longer, more complex, written consent forms creating barriers to participant understanding. A recent meta-analysis concluded that randomized comparisons were needed.

Methods

We conducted a cluster-randomized non-inferiority comparison of a standard versus concise consent form within a multinational trial studying the timing of starting antiretroviral therapy in HIV-1 adults (START). Interested sites were randomized to standard or concise consent forms for all individuals signing START consent. Participants completed a survey measuring comprehension of study information and satisfaction with the consent process. Site principal investigators used site resident questionnaires. The option to remove consent forms from the public domain is available.


Challenges



- ▶ Complex Science
- ▶ Health literacy and capacity
- ▶ Measuring understanding
- ▶ Different kinds of “mis-understanding”
 - ▶ Misconception
 - ▶ Mis-estimation
 - ▶ Optimism *Hornig & Grady IRB 2003*
- ▶ Knowledge v. appreciation

Voluntariness

- ▶ Able to make a voluntary choice?
- ▶ No deception, coercion, undue influence



Voluntariness



- ▶ Deception- concealment or distortion of the truth in order to mislead
- ▶ Coercion- compelling another party to act by force or by threatening to make them worse off
- ▶ Undue inducement- an offer that distorts judgement or entices someone to participate in research that is contrary to their interests.

Possible influences on voluntariness




- ▶ Dependent position
- ▶ Power relationship
- ▶ Pressure from others (family, friends)
- ▶ Trust in health care provider
- ▶ Restricted choices?
- ▶ Illness?
- ▶ Incentives?

Voluntariness

- ▶ Pressure from others
 - ▶ 2%- 25% (ACHRE 1996, van Stuversten et al 1998, Pace et al 2005)
 - ▶ 58% from child's disease (Pace et al 2005)
- ▶ Knew they could quit
 - ▶ 44% Swedish women in gyn trial, 88% Thai HIV vaccine participants, 90% US Cancer patients (Lynoe et al 1991 and 2001; Pitisuttithum et al 1997, Joffe et al 2001)
- ▶ Decline participation
 - ▶ Range of actual decliners

Fig. 2. Participants' understanding of components of informed consent in clinical trials, by meta-analysis^a



^a The number of studies included in the evaluation of each component is given.

Informed consent


▶ The BASICS

▶ *CHANGES*

▶ ENDURING AND EMERGING
CHALLENGES




Paradigmatic clinical research



MEDICAL RECORD	CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY
	• Adult Patient or • Parent, for Minor Patient
INSTITUTE:	
STUDY NUMBER:	PRINCIPAL INVESTIGATOR:
STUDY TITLE:	
Initial Review Approved by the IRB on _____	Date Printed to Web: _____
Standard	
INTRODUCTION	
We invite you to take part in a research study at the National Institutes of Health (NIH).	
First, we need to know that:	
Taking part in NIH research is entirely voluntary.	
You may choose not to take part, or you may withdraw from the study at any time. In either case, you will not lose any benefits to which you are otherwise entitled. However, to receive care at the NIH, you must be taking part in a study or be under evaluation for study participation.	

Journal Example	
Example Author Manuscript Title	
Example Author One • Example Author Two • Example Author Three	
ARTICLE	
<p>Introduction</p> <p>Research in this field has been limited to the study of the effects of the drug on the brain. The present study was designed to investigate the effects of the drug on the brain and the effects of the drug on the brain. The present study was designed to investigate the effects of the drug on the brain and the effects of the drug on the brain.</p>	<p>Methods</p> <p>The present study was designed to investigate the effects of the drug on the brain and the effects of the drug on the brain. The present study was designed to investigate the effects of the drug on the brain and the effects of the drug on the brain.</p>

Paradigmatic clinical research



MEDICAL RECORD	CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY • Adult Patient or • Patient, for Minor Patient
INSTITUTION:	
STUDY NUMBER:	PRINCIPAL INVESTIGATOR:
STUDY TITLE:	
Initial Review Approved by the IRB on _____ Date Filled by IRB: _____ Signature	
INTRODUCTION	
We invite you to take part in a research study at the National Institutes of Health (NIH).	
First, we want you to know that:	
Taking part in NIH research is entirely voluntary.	
You may choose not to take part, or you may withdraw from the study at any time. In either case, you will not lose any benefits to which you are otherwise entitled. However, to receive care at the NIH, you must be taking part in a study or be under evaluation for study participation.	



Research with Data and Biospecimens




Research with Data and Biospecimens



MEDICAL RECORD	CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY • Adult Patient or • Parent, for Minor Patient
INSTITUTE:	
STUDY NUMBER:	PRINCIPAL INVESTIGATOR:
STUDY TITLE:	
Initial Review Approved by the IRB on _____ Date Posted to Web: _____	Standard
INTRODUCTION	
We invite you to take part in a research study at the National Institutes of Health (NIH).	
First, we want you to know that:	
Taking part in NIH research is entirely voluntary.	
You may choose not to take part, or you may withdraw from the study at any time. In either case, you will not lose any benefits to which you are otherwise entitled. However, to receive care at the NIH, you must be taking part in a study or be under evaluation for study participation.	



No consensus on acceptable consent

	TYPE OF CONSENT	DESCRIPTION
<p>Less Control, Less burden</p>  <p>More control, more burden</p>	No consent	Do not obtain donor consent
	Blanket	Consent to future research with no limitations
	Broad*	Consent to future research with specified limitations
	Checklist	Donors choose which types of future studies are allowed
	Study specific	Consent for each specific future study

Pragmatic trials



CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY


Medical History: _____
Study Number: _____
Principal Investigator: _____
Study Title: _____
Date Approved: _____
Date Published: _____

INTRODUCTION


We invite you to take part in a research study at the National Institutes of Health (NIH). First, we want you to know that:

Taking part in NIH research is entirely voluntary.




You may choose not to take part, or you may withdraw from the study at any time. In either case, you will not lose any benefits to which you are otherwise entitled. However, to receive any of the NIH, you must be taking part in study or be under evaluation for study participation.



Pragmatic trials



Research with big data



Information technologies



© Moxi Group

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-D-0390]

Use of Electronic Informed Consent—Questions and Answers; Guidance for Institutional Review Boards, Investigators, and Sponsors; Availability

AGENCY: Food and Drug Administration and Office for Human Research Protections, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP), Department of Health and Human Services (HHS), are announcing the availability of a guidance entitled “Use of Electronic Informed Consent—Questions and Answers.” The guidance is intended for institutional review boards (IRBs), investigators, and sponsors engaged in or responsible for oversight of human subject research under HHS and/or FDA regulations. The guidance provides recommendations on the use of electronic systems and processes that may employ multiple electronic media to obtain informed consent for both HHS-regulated human subject research and FDA-regulated clinical investigations of medical products, including human drug and biological products, medical devices, and combinations thereof. This guidance finalizes the draft guidance entitled “Use of Electronic Informed Consent in Clinical Investigations—Questions and Answers” issued in March 2015.

DATES: Submit either electronic or written comments on Agency guidances at any time.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <http://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically,

as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <http://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).

Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand delivery/Courier (for written/paper submissions):** Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in “Instructions.”

Instructions: All submissions received must include the Docket No. FDA-2015-D-0390 for “Use of Electronic Informed Consent—Questions and Answers; Guidance for Institutional Review Boards, Investigators, and Sponsors; Availability.” Received comments will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at <http://www.regulations.gov> or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.” The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The

comments and you must identify this information as “confidential.” Any information marked as “confidential” will not be disclosed except in accordance with 21 CFR 312.63, applicable disclosure requirements, information about FDA’s policies on comments to public. (81 FR 56469, September 22, 2016; www.regulations.gov; <http://www.fda.gov/regulatoryinformation/default.htm>).

Docket: Read back comments received electronically at www.regulations.gov docket number HFA-305-2015-0001 heading “Search” and/or go to the Division of Dockets Management (HFA-305), 1061, Rockville, MD 20852.

See section 1016.17 of 21 CFR for **INFORMATION** regarding written requests for guidance and for electronic guidance documents.

FOR FURTHER INFORMATION: Cheryl Grandinetti, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 3348, Silver Spring, MD 20993-0002, 301-796-2500; Nicole Wolanski, Office of Good Clinical Practice, Office of Special Medical Programs, Office of Medical Products and Tobacco, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5108, Silver Spring, MD 20993, 301 796-6570; Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911; Irfan Khan, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 3459, Silver Spring, MD 20993, 1-800-638-2041 or 301-796-7100; or Irene Stith-Coleman, Office for Human Research Protections, 1101 Wootton Pkwy., suite 200, Rockville, MD 20852, 240-453-6900.

SUPPLEMENTARY INFORMATION:
I. Background

“...electronic consent refers to the use of electronic systems and processes that may employ multiple electronic media, including text, graphics, audio, video, podcasts, passive and interactive Web sites, biological recognition devices, and card readers, to convey information related to the study and to obtain and document informed consent.”

Components and Challenges of Informed Consent with Traditional Paper Forms and Electronic Methods.

Table 1. Components and Challenges of Informed Consent with Traditional Paper Forms and Electronic Methods.

Component	Traditional Paper Informed Consent	Electronic and Digital Informed Consent	Challenges and Areas for Research
Disclosure	Information is written, usually on paper Discussion with investigator takes place, usually face to face	Consent can involve electronic information, multimedia information, video graphics, and interactive computer interfaces Investigator can be remote in time or place from participant	All types of disclosure require determining the appropriate content (amount and complexity of information) for disclosure User-friendly disclosure is needed Amount and style of information tailored to electronic platforms need to be determined
Understanding	Investigator and participant discuss information Participant asks questions Investigator assesses understanding, in some cases using questions, structured quizzes, other methods	Interaction can take place during disclosure Questions and assessment of understanding are easily built in Ongoing engagement is enabled Links to additional information can be included	Evidence indicates that people do not read click-through agreements on computers and mobile devices Information should be engaging and user-friendly to promote reading and understanding It may be difficult to assess capacity and understanding Empirical evidence to date indicates that video and multimedia consent strategies have not resulted in consistent advantages or disadvantages with regard to participant understanding ⁴⁷
Voluntariness	Investigator asks participant to make a choice in a setting free from coercion and undue influence Research team observes participant's body language and any hesitation	Some electronic systems facilitate participant control Participant can easily sign off or disengage Participant can decline	It may be difficult to assess voluntary choice without the clues of body language and tone It may be difficult to verify the identity of the person consenting Some data collection is passive In some cases, contributing data is a required part of the arrangement
Authorization	Paper consent document is signed Copies of document are kept in records	Options might include clicking agreement or an electronic signature Records of agreement are kept electronically	It may be difficult to verify the identity of the authorizing person

Dynamic consent



Interactive technology based platform.

Not “... locked in time to the beginning of the research process. Depending upon the nature of the research enterprise, participants could consent to a broad range of uses of their samples and data, or opt to be approached on a case-by-case basis, or set different preferences for different types of research. These preferences can be ‘opt ins’ or ‘opt outs’: participants can tailor their profiles to receive no information for specified periods of time or to give a broad consent if they so wish.”

Kaye et al 2015

App based consent

- ▶ http://www.nejm.org/action/showMediaPlayer?doi=10.1056%2FNEJMra1603773&aid=NEJMra1603773_attach_1&area=

Interactive consent

<https://www.youtube.com/watch?v=dM7InKSzW7g>

Improving informed consent

- ▶ More is not always better
- ▶ Timing matters
- ▶ Technology can help



Schenker Y and Meisel A, *JAMA* 2011

Informed consent


- 
- No consent
 - Waiver

- Notification
- Simplified disclosure

- Full informed consent
- Full in person informed consent

Informed consent

- ▶ As research and technology evolve, maintain clarity about the purpose(s) of informed consent



- ▶ Quality training of researchers, research teams, clinicians, and IRB members

- ▶ Creativity and evidence



Conclusions



Informed consent is a process based on respect for persons, that also promotes participant welfare, respects values, offers control, promotes trust, complies with regulations, and helps to ensure integrity.



Changes in research methodologies, information technologies, participant engagement, regulations, and our understanding of informed consent offer opportunities for innovative evidence-based strategies for informed consent.